Dabigatrana new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature

  1. Marta Muñoz Corcuera 1
  2. Lucía Ramírez Martínez Acitores 2
  3. Rosa Mª López-Pintor Muñoz 3
  4. Elisabeth Casañas Gil 4
  5. Gonzalo Hernández Vallejo 5
  1. 1 DDS, PhD. Assistant professor. Oral medicine specialist, Complutense University, Madrid, Spain
  2. 2 DDS. Assistant professor. Oral medicine specialist, Complutense University, Madrid, Spain
  3. 3 DDS, PhD. Associate professor. Department of Oral medicine and Orofacial surgery. Faculty of Odontology. Complutense University, Madrid, Spain
  4. 4 DDS, PhD Student. Assistant professor. Oral medicine specialist. Complutense University, Madrid, Spain
  5. 5 MD, DDS, PhD. Professor. Department of Oral Medicine and Orofacial Surgery. Faculty of Odontology. Complutense Univer-sity. Madrid, Spain
Mostrar afiliaciones +
Revista:
Medicina oral, patología oral y cirugía bucal. Ed. inglesa

ISSN: 1698-6946

Año de publicación: 2016

Volumen: 21

Número: 6

Páginas: 13

Tipo: Artículo

DOI: 10.4317/MEDORAL.21202 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Medicina oral, patología oral y cirugía bucal. Ed. inglesa

Resumen

Dabigatran is a newly commercialized drug that is replacing other anticoagulants in the prevention of venous thromboembolism, stroke and systemic arterial valve embolism. It acts directly on thrombin presenting in a dynamic and predictable way, which does not require monitoring these patients. Therefore, we consider the need to assess whether their use increases the risk of bleeding involved before any dental treatment. We performed a systematic review with a bibliographic search in PubMed/Medline along with the Cochrane Library. We excluded articles dealing with all anticoagulants other than dabigatran, and works about surgical treatments in anatomical locations other than the oral cavity. We included a total of 13 papers of which 1 was a randomized clinical trial, 9 narrative literature reviews, 1 case series, 2 clinical cases and 1 expert opinion. Because we did not obtain any properly designed clinical trials, we were unable to conduct a meta-analysis. Currently, there is no consensus on the procedure to be followed in patients taking dabigatran. However, all authors agree to treat each case individually in accordance to the risk of embolism, postoperative bleeding and renal function. Also, it is necessary to perform minimally invasive interventions, and take the appropriate local anti-hemolytic measures.

Referencias bibliográficas

  • Quintero Gonzalez, JA. (2010). Fifty years of clinical use of warfarin. Invest Clin. 51. 269
  • Zheng, Y, Sorensen, SV, Gonschior, AK, Noack, H, Heinrich-Nols, J, Sunderland, T. (2014). Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clin Ther. 36. 2015
  • Nishio, H, Ieko, M, Nakabayashi, T. (2008). New therapeutic option for thromboembolism--dabigatran etexilate. Expert Opin Pharmacother. 9. 2509
  • Golembiewski, JA. (2011). Dabigatran: a new oral anticoagulant. J Perianesth Nurs. 26. 420
  • Cohen, HV, Quek, SY, Subramanian, G, Abbas, A. (2013). New antiplatelet and anticoagulant drugs. Considerations for dental patient management. JNJ Dent Assoc. 84. 30
  • Kahn, SR, Lim, W, Dunn, AS, Cushman, M, Dentali, F, Akl, EA. (2012). American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141. 195-226
  • Healey, JS, Eikelboom, J, Douketis, J, Wallentin, L, Oldgren, J, Yang, S. (2012). Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 126. 343
  • Gómez-Moreno, G, Aguilar-Salvatierra, A, Martín-Piedra, MA, Guardia, J, Calvo-Guirado, JL, Cabrera, M. (2010). Dabigatran and rivaroxaban, new oral anticoagulants, new approaches in dentistry. J Clin Exp Dent. 2. 1-5
  • Little, JW. (2012). New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 113. 575
  • Firriolo, FJ, Hupp, WS. (2012). Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 113. 431
  • Davis, C, Robertson, C, Shivakumar, S, Lee, M. (2013). Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 79. 74
  • Weitz, JI, Quinlan, DJ, Eikelboom, JW. (2012). Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 126. 2428
  • Van Diermen, DE, van der Waal, I, Hoogstraten, J. (2013). Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 116. 709
  • Kerr, R, Ogden, G, Sime, G. (2013). Anticoagulant guidelines. Br Dent J. 214. 430
  • Romond, KK, Miller, CS, Henry, RG. (2013). Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 116. 191
  • Breik, O, Cheng, A, Sambrook, P, Goss, A. (2014). Protocol in managing oral surgical patients taking dabigatran. Aust Dent J. 59. 296-301
  • Curtin, C, Hayes, JM, Hayes, J. (2014). Dental Implications of new oral anticoagulants for atrial fibrilacion. Dent Update. 41. 526
  • Sivolella, S, De Biagi, M, Brunello, G, Berengo, M, Pengo, V. (2015). Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. Odontology. 103. 258
  • van Ryn, J, Stangier, J, Haertter, S, Liesenfeld, KH, Wienen, W, Feuring, M. (2010). Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 103. 1116
  • Miller, CS, Grandi, SM, Shimony, A, Filion, KB, Eisenberg, MJ. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 110. 453
  • Schiele, F, van Ryn, J, Canada, K, Newsome, C, Sepulveda, E, Park, J. (2013). A specific antidote for dabigatran: functional and structural characterization. Blood. 121. 3554
Fuente de los datos: Dialnet